The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).

Condition:   Peripheral T Cell Lymphoma Intervention:   Drug: F520 Sponsor:   Shandong New Time Pharmaceutical Co., LTD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials